NCT00732875View on ClinicalTrials.gov

A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

Infliximab + methotrexate (MTX)

Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00732875 - A Trial of Anti-TNF Chimeric Monoclonal Antibody (cA2) in Korean Patients With Active Rheumatoid Arthritis Despite Methorexate (Extension Part)(Study P05645)(COMPLETED) | Biotech Hunter | Biotech Hunter